BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Curtis NJ, Noble F, Bailey IS, Kelly JJ, Byrne JP, Underwood TJ. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. J Surg Oncol. 2014;109:202-207. [PMID: 24243140 DOI: 10.1002/jso.23484] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Lin M, Li P, Xie J, Lin J, Lu J, Chen Q, Cao L, Lin M, Zheng C, Huang C. The prognostic relevance of parapyloric lymph node metastasis in Siewert type II/III adenocarcinoma of the esophagogastric junction. European Journal of Surgical Oncology 2017;43:2333-40. [DOI: 10.1016/j.ejso.2017.08.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
2 Johnston FM, Beckman M. Updates on Management of Gastric Cancer. Curr Oncol Rep 2019;21:67. [PMID: 31236716 DOI: 10.1007/s11912-019-0820-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 14.0] [Reference Citation Analysis]
3 Shah PM, Gerdes H. Endoscopic options for early stage esophageal cancer. J Gastrointest Oncol. 2015;6:20-30. [PMID: 25642334 DOI: 10.3978/j.issn.2078-6891.2014.096] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
4 Rizk N. Gastroesophageal Junction Tumors. Ann Surg Oncol 2016;23:3798-800. [DOI: 10.1245/s10434-016-5427-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ferrer-Torres D, Nancarrow DJ, Kuick R, Thomas DG, Nadal E, Lin J, Chang AC, Reddy RM, Orringer MB, Taylor JM, Wang TD, Beer DG. Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas. Oncotarget 2016;7:54867-82. [PMID: 27363029 DOI: 10.18632/oncotarget.10253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
6 Han WH, Eom BW, Yoon HM, Reim D, Kim YW, Kim MS, Lee JM, Ryu KW. The optimal extent of lymph node dissection in gastroesophageal junctional cancer: retrospective case control study. BMC Cancer 2019;19:719. [PMID: 31331305 DOI: 10.1186/s12885-019-5922-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
7 Fuster D, Mayoral M, Rubello D, Pineda E, Fernández-Esparrach G, Pagès M, Colletti PM, Pons F. Is there a role for PET/CT with esophagogastric junction adenocarcinoma? Clin Nucl Med. 2015;40:e201-e207. [PMID: 25546207 DOI: 10.1097/RLU.0000000000000661] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Azari FS, Roses RE. Management of Early Stage Gastric and Gastroesophageal Junction Malignancies. Surg Clin North Am. 2019;99:439-456. [PMID: 31047034 DOI: 10.1016/j.suc.2019.02.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Maktabi M, Köhler H, Ivanova M, Jansen-Winkeln B, Takoh J, Niebisch S, Rabe SM, Neumuth T, Gockel I, Chalopin C. Tissue classification of oncologic esophageal resectates based on hyperspectral data. Int J Comput Assist Radiol Surg 2019;14:1651-61. [PMID: 31222672 DOI: 10.1007/s11548-019-02016-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
10 Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. JAMA Oncol 2017;3:1520-8. [PMID: 28687830 DOI: 10.1001/jamaoncol.2017.1598] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 16.2] [Reference Citation Analysis]
11 Imamura Y, Watanabe M, Oki E, Morita M, Baba H. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. Ann Gastroenterol Surg 2021;5:46-59. [PMID: 33532680 DOI: 10.1002/ags3.12406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Mullen JT, Kwak EL, Hong TS. What's the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer. Ann Surg Oncol 2016;23:3780-5. [PMID: 27459983 DOI: 10.1245/s10434-016-5426-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
13 Fuchs H, Hölscher AH, Leers J, Bludau M, Brinkmann S, Schröder W, Alakus H, Mönig S, Gutschow CA. Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy? Gastric Cancer 2016;19:312-7. [PMID: 25627475 DOI: 10.1007/s10120-015-0466-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
14 McCain S, Trainor J, McManus DT, McMenamin ÚC, McQuaid S, Bingham V, James JA, Salto-Tellez M, Turkington RC, Coleman HG. Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study. Oncotarget 2018;9:34347-56. [PMID: 30344947 DOI: 10.18632/oncotarget.26151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Rahman S, Thomas B, Maynard N, Park MH, Wahedally M, Trudgill N, Crosby T, Cromwell DA, Underwood TJ. Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery. Br J Surg 2021:znab427. [PMID: 34910129 DOI: 10.1093/bjs/znab427] [Reference Citation Analysis]
16 Chen K, Deng X, Yang Z, Yu D, Zhang X, Zhang J, Xie D, He Z, Cheng D. Survival nomogram for patients with metastatic siewert type II adenocarcinoma of the esophagogastric junction: a population-based study. Expert Rev Gastroenterol Hepatol 2020;14:757-64. [PMID: 32552040 DOI: 10.1080/17474124.2020.1784726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Moureau-Zabotto L, Teissier E, Cowen D, Azria D, Ellis S, Resbeut M. Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction. Gastroenterol Res Pract 2015;2015:404203. [PMID: 26448741 DOI: 10.1155/2015/404203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 McCain RS, McManus DT, McQuaid S, James JA, Salto-Tellez M, Reid NB, Craig S, Chisambo C, Bingham V, McCarron E, Parkes E, Turkington RC, Coleman HG. Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study. Cancer Causes Control 2020;31:1-11. [PMID: 31786674 DOI: 10.1007/s10552-019-01247-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
19 Thomaschewski M, Hummel R, Petrova E, Knief J, Wellner UF, Keck T, Bausch D. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. World J Gastroenterol 2018; 24(13): 1429-1439 [PMID: 29632424 DOI: 10.3748/wjg.v24.i13.1429] [Reference Citation Analysis]
20 Song KJ, Arndt AT. Is a Novel Nomogram Better Than TNM Staging at Predicting Survival in Siewert Type 2 Adenocarcinoma? Ann Surg Oncol 2019;26:1182-3. [PMID: 30771117 DOI: 10.1245/s10434-019-07242-w] [Reference Citation Analysis]
21 Nowicki-Osuch K, Zhuang L, Jammula S, Bleaney CW, Mahbubani KT, Devonshire G, Katz-Summercorn A, Eling N, Wilbrey-Clark A, Madissoon E, Gamble J, Di Pietro M, O'Donovan M, Meyer KB, Saeb-Parsy K, Sharrocks AD, Teichmann SA, Marioni JC, Fitzgerald RC. Molecular phenotyping reveals the identity of Barrett's esophagus and its malignant transition. Science 2021;373:760-7. [PMID: 34385390 DOI: 10.1126/science.abd1449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhao B, Zhang Z, Mo D, Lu Y, Hu Y, Yu J, Liu H, Li G. Optimal Extent of Transhiatal Gastrectomy and Lymphadenectomy for the Stomach-Predominant Adenocarcinoma of Esophagogastric Junction: Retrospective Single-Institution Study in China. Front Oncol 2018;8:639. [PMID: 30719422 DOI: 10.3389/fonc.2018.00639] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Kulig P, Sierzega M, Pach R, Kolodziejczyk P, Kulig J; Polish Gastric Cancer Study Group. Differences in prognosis of Siewert II and III oesophagogastric junction cancers are determined by the baseline tumour staging but not its anatomical location. Eur J Surg Oncol. 2016;42:1215-1221. [PMID: 27241921 DOI: 10.1016/j.ejso.2016.04.061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
24 Di Leo A, Zanoni A. Siewert III adenocarcinoma: treatment update. Updates Surg. 2017;69:319-325. [PMID: 28303519 DOI: 10.1007/s13304-017-0429-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
25 Cowie A, Noble F, Underwood T. Strategies to improve outcomes in esophageal adenocarcinoma. Expert Rev Anticancer Ther 2014;14:677-87. [PMID: 24621143 DOI: 10.1586/14737140.2014.895668] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
26 Kitagawa H, Namikawa T, Iwabu J, Fujisawa K, Kobayashi M, Hanazaki K. Outcomes of abdominal esophageal cancer patients who were treated with esophagectomy. Mol Clin Oncol 2018;8:286-91. [PMID: 29435289 DOI: 10.3892/mco.2017.1510] [Reference Citation Analysis]
27 Chen K, Deng X, Yang Z, Yu D, Zhang X, Li W, Xie D, He Z, Cheng D. Sites of distant metastases and the cancer-specific survival of metastatic Siewert type II esophagogastric junction adenocarcinoma: a population-based study. Expert Rev Gastroenterol Hepatol 2020;14:491-7. [PMID: 32324423 DOI: 10.1080/17474124.2020.1760839] [Reference Citation Analysis]